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Abstract 24 
Productive picornavirus infection requires the hijack of host cell pathways to aid with the 25 
different stages of virus entry, synthesis of the viral polyprotein and viral genome 26 
replication. Many picornaviruses, including foot-and-mouth disease virus (FMDV), 27 
assemble capsids via the multimerisation of several copies of a single capsid precursor 28 
protein into a pentameric subunit which further encapsidates the RNA. Pentamer 29 
formation is preceded by co- and post-translational modification of the capsid precursor 30 
(P1-2A) by viral and cellular enzymes, and the subsequent rearrangement of P1-2A into 31 
a structure amenable to pentamer formation. We have developed a cell-free system to 32 
study FMDV pentamer assembly using recombinantly expressed FMDV capsid 33 
precursor and 3C protease. Using this assay, we have shown that two structurally 34 
different inhibitors of the cellular chaperone heat shock protein 90 (hsp90), impeded 35 
FMDV capsid precursor processing and subsequent pentamer formation. Treatment of 36 
FMDV permissive cells with the hsp90 inhibitor prior to infection reduced the endpoint 37 
titre by more than ten-fold while not affecting the activity of a sub-genomic replicon 38 
indicating that translation and replication of viral RNA were unaffected by the drug.   39 
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Importance  40 
Foot-and-mouth disease virus (FMDV), of the Picornaviridae family is a pathogen of 41 
huge economic importance to the livestock industry due to its effect on the restriction of 42 
livestock movement and necessary control measures required following an outbreak. 43 
The study of FMDV capsid assembly, and picornavirus capsid assembly more 44 
generally, has tended to be focused upon the formation of capsids from pentameric 45 
intermediates, or the immediate co-translational modification of the capsid precursor 46 
protein. Here we describe a system to analyse the early stages of FMDV pentameric 47 
capsid intermediate assembly and demonstrate a novel requirement for the cellular 48 
chaperone hsp90 in the formation of these pentameric intermediates. We show the 49 
added complexity involved for this process to occur which could be the bases for a 50 
novel antiviral control mechanism for FMDV.  51 
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Introduction 52 
The Picornaviridae are a diverse family of viruses with icosahedral capsids and a 53 
positive sense, single-stranded RNA genome. They are generally considered to be non-54 
enveloped, although some may acquire an envelope as an alternative means of 55 
transmission (1, 2). The picornavirus family contains important pathogens of humans 56 
and animals including poliovirus and human rhinovirus in the Enterovirus genus and 57 
foot-and-mouth disease virus (FMDV) in the Aphthovirus genus. FMDV infects multiple 58 
livestock and wildlife species and is a significant global economic burden and threat to 59 
food security. Foot-and-mouth disease is characterised by vesicle formation around the 60 
mouth and on the feet, fever, lameness, abortion and occasionally death of young 61 
animals in severe cases (3).  62 
 63 
The picornavirus genome encodes both structural and non-structural proteins which are 64 
translated from a single open-reading frame as a polyprotein. In FMDV co-translational 65 
processing results in the generation of a capsid precursor, P1-2A (FMDV genome 66 
structure fig. 1A).  This capsid precursor is proteolytically processed by a virally 67 
encoded protease 3Cpro, to form cleavage products VP0, VP1 and VP3 which remain 68 
associated as the protomer, the basic subunit of capsid assembly (4). Five protomers 69 
multimerise to form the pentameric capsid intermediate, twelve of which further 70 
assemble into the viral capsid (5, 6). If RNA is encapsidated during the assembly 71 
process, VP0 is cleaved into VP2 and VP4, and infectious virions are formed, however 72 
capsids lacking RNA (empty capsids) have also been shown to form in cells infected by 73 
many picornaviruses including FMDV (6-10). Recombinant empty capsids can be 74 
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generated through the expression of the capsid precursor along with 3C protease in 75 
heterologous systems (11-14).    76 
 77 
The formation of empty capsids from pentamers is often referred to as a self-assembly 78 
process, as it has been demonstrated that a sufficient concentration of pentamers is all 79 
that is necessary for capsids to form (15, 16), whereas the assembly of pentameric 80 
capsid subunits is more complex.  In many picornaviruses including FMDV, the capsid 81 
precursor is N-terminally myristoylated by host enzymes (17) and this is thought to 82 
provide stability to subsequent assembly steps (11, 18-20) by forming inter-protomer 83 
interactions (19) essential for the assembly of infectious virions.  It is also accepted that 84 
precursor processing by the 3C viral protease (3Cpro) is an essential step in 85 
morphogenesis (6, 18, 21, 22) as the termini of the capsid proteins are separated in the 86 
empty capsid (23, 24) and virion structures (25-28). Processing is thought to enable 87 
interactions to occur which stabilise the formation of pentamers (21, 29).  While the 88 
residues at P1 and P1’ of the 3Cpro cleavage sites in the capsid precursor are critical for 89 
efficient processing (30), the protease recognition sequences span 8 residues (P4-P4’) 90 
which is thought to be associated with the ability of the enzyme binding cleft to 91 
accommodate the capsid precursor substrate (31). However, truncations or mutations to 92 
sites distant from the cleavage sites can prevent or impact the efficiency of processing 93 
(32-34), suggesting that the capsid precursor is required to be presented in the correct 94 
conformation to the viral protease in order for processing to occur efficiently.    95 
 96 
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Some viruses have been shown to interact with components of the cellular chaperone 97 
machinery that facilitates protein folding and homeostasis (36), most likely reflecting a 98 
requirement for assisted protein folding as a result of the rapid rate of production of viral 99 
proteins. The growth of many viruses are impaired by inhibitors of hsp90 (35) including 100 
several picornaviruses (37-41). Specifically, for several enteroviruses, the ATP-101 
dependent heat shock proteins (hsp) 70 and 90, which are major components of the 102 
cellular chaperone machinery have been shown to interact with P1 (the enterovirus 103 
capsid precursor polyprotein) (37, 42). This interaction with hsp90 and co-chaperone 104 
p23, protects P1 from proteasomal degradation and it is thought to fold P1 into a 105 
confirmation allowing it to be processed by the viral protease (37). As described above, 106 
processing is a critical event in the assembly of infectious virions. The major capsid 107 
protein (VP1) of human and murine noroviruses in the related Caliciviridae family of 108 
viruses has also been shown to interact with hsp90, thereby protecting it from 109 
degradation (44), suggesting a conserved mode of action for hsp90 between different 110 
picorna-like virus clades (45). 111 
 112 
We previously established cell-free systems to study the assembly of FMDV capsid 113 
subunits (18). In this study, we have used established hsp90 inhibitors (46, 47) to show 114 
that hsp90 is required for efficient growth of FMDV in cell culture and for P1-2A 115 
processing and pentamer assembly in cell-free assays for assembly of capsid subunits.   116 
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Results 117 
Hsp90 inhibition reduces FMDV growth independent of viral RNA replication and 118 
protein translation. To demonstrate a requirement for hsp90 in the lifecycle of FMDV, 119 
we sought to quantify the effect on viral growth using 17-DMAG a well-characterised 120 
inhibitor of hsp90. 17-DMAG is a water-soluble derivative of Geldanamycin (GA), a 121 
benzoquinone ansamycin antibiotic which has a structure that is highly similar to the 122 
conformation that ATP adopts when occupying its binding site in the hsp90 dimer (48, 123 
49).  124 
 125 
BHK-21 cells were pre-treated with 0.5 µM and 10 µM 17-DMAG, prior to infection with 126 
FMDV at MOI 1 with drug treatments maintained in the cell culture media throughout the 127 
experiment. The cultures were lysed by freeze-thaw after one replication cycle (8 hrs 128 
post infection) and the levels of infectious virus were quantified by end point dilution 129 
assay. Treatment with both concentrations of 17-DMAG resulted in a greater than 10-130 
fold reduction in virus titre (P≤0.01, one-way analysis of variance (ANOVA) compared to 131 
the mock-treated control (fig. 2A).  132 
 133 
Previous studies showed that inhibition of hsp90 does not affect the replication of a 134 
poliovirus sub-genomic replicon RNA (37), or the levels of viral RNA in cells infected by 135 
the related enterovirus 71 (40) suggesting that hsp90 does not inhibit viral RNA 136 
replication or translation in these systems. To determine if this was also true for FMDV, 137 
porcine IB-RS-2 cells were treated with 0.5µM 17-DMAG, the well-characterised 138 
picornavirus replication inhibitor guanidine hydrochloride (GuHCl; 3 mM) (50) or mock 139 
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treated before being transfected with an FMDV sub-genomic replicon RNA, in which the 140 
majority of the capsid coding region was replaced with sequence encoding Renilla 141 
reniformis luciferase (as described by Tulloch and colleagues (51) but with luciferase 142 
replacing GFP (fig. 1B)). Drug treatments were maintained in the cell culture media 143 
throughout the experiment. Luminescence readings were collected between one and 144 
five hours post-transfection. No significant differences were observed between 17-145 
DMAG and mock treated cells whereas a significant reduction (P≤0.001, two-way 146 
ANOVA) in luminescence signal was observed from 3.5 hours and onwards in the 147 
GuHCl control (fig. 2B). This result demonstrated that 17-DMAG had no effect on the 148 
expression of luciferase from the FMDV replicon suggesting that RNA replication and 149 
translation were unaffected by inhibition of hsp90 and also that the 3C protease activity 150 
was not directly affected by the drug.  151 
 152 
The cytotoxicity of 17-DMAG was determined for baby hamster kidney (BHK-21) and 153 
porcine kidney (IB-RS-2) cell lines to demonstrate that toxicity was not the cause of the 154 
reduction in virus titre. A luminescence-based cell viability assay (ToxGlo, Promega) 155 
was used and showed the drug to be non-toxic at 20 µM and below (fig. 2C).  156 
 157 
To demonstrate that FMDV was inhibited by 17DMAG in a dose-dependent manner, 158 
BHK-21 cells were treated with a 2.5-fold dilution series of the inhibitor and 159 
subsequently infected with FMDV at low MOI (~0.01) in a multicycle infection assay. At 160 
3 days post infection the Toxglo viability assay was used to demonstrate the dose at 161 
which the cells were protected from viral cytopathic effect (cpe). Infection of the cells in 162 
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the absence of the inhibitor resulted in extensive cpe (causing an approximate 85% 163 
drop in viability in this assay compared to uninfected controls). In contrast, the cells 164 
were partially protected at a 17DMAG concentration of 0.065µM and fully protected at 165 
concentrations of 17DMAG at 0.163µM and above (fig. 3A). To confirm the utility of this 166 
assay in determining the antiviral-dose response of FMDV, GuHCl was used as a 167 
control. Again in the absence of inhibitor, the drop in cell viability due to infection was 168 
about 85%, and in this instance GuHCl protected the cells from cpe at concentrations 169 
above 2.5mM (fig. 3B). 170 
 171 
Capsid precursor processing and pentamer assembly is supported in a cell-free 172 
system. Existing evidence points to the involvement of hsp90 in the early stages of 173 
assembly of PV and other closely related picornaviruses (37, 40, 42). Therefore to 174 
investigate this part of the FMDV life cycle, a cell-free assembly assay was developed 175 
using recombinant proteins. The FMDV 3Cpro was generated from a plasmid expression 176 
construct (fig. 1C) in bacteria and purified as previously described (52). A T7 promoter-177 
driven expression plasmid encoding the capsid polyprotein followed by a hexa-histidine 178 
tag at the C terminus was used to produce radiolabelled capsid precursor protein in 179 
rabbit reticulocyte lysates (RRLs). The precursor protein was engineered to contain the 180 
first four amino acids of 2A (Δ2A) to retain a native 3Cpro cleavage recognition site such 181 
that processing would generate the authentic C-terminus of P1 (fig. 1D, pBG200-P1-182 
Δ2A). To ensure complete processing of P1-Δ2A by 3Cpro, RRLs were programmed with 183 
pBG200-P1-Δ2A followed by treatment with a 2-fold dilution series of purified 3Cpro. This 184 
determined that a final 3Cpro concentration of 1 µM was sufficient to process P1-Δ2A 185 
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into the expected products VP0, VP1 and VP3. At lower 3C concentrations VP0-VP3 186 
and VP3-VP1 intermediates were also observed (fig. 4A).  187 
 188 
The presence of capsid precursors, protomers and assembled pentamers was 189 
determined by sedimentation of samples through sucrose density gradients (SDGs). 190 
Proteins with known sedimentation coefficients (BSA 4.6S, IgG 7.1S, and dissociated 191 
FMDV pentamers 12S) (53) were used as markers (Fig. 4B). Unprocessed radiolabelled 192 
capsid precursor P1Δ2A expressed in RRL, sedimented as a single peak of radioactivity 193 
approximately one-third through the gradient (fig. 4C; solid circles) at the expected 194 
position (5S). Samples of capsid precursor that had been processed by 3Cpro resulted in 195 
a peak at this position as well as a second peak at approximately two-thirds through the 196 
gradient at the expected position of pentamer (14S) (fig. 4C; open circles). From the 197 
processing assays, it was clear that the precursor had been fully processed so therefore 198 
the 5S peak on this gradient was likely protomer (processed capsid precursor) that had 199 
not assembled into pentamers. In addition to the analysis of pentamer formation as 200 
described above, the assembly reactions were also analysed in parallel for the 201 
assembly of capsids, using different SDG conditions suitable for resolving capsids from 202 
smaller precursors. This determined that in the one hour processing and assembly 203 
assay, no empty capsids were formed (data not shown), likely due to pentamers not 204 
reaching the threshold concentration required for capsid self-assembly (15, 16). This 205 
demonstrated the utility of this assay as a method to specifically analyse the pentamer 206 
assembly step. To validate the assay, a mutant construct (fig. 1D pBG200-P1-Δ2A 207 
G2A) was generated with a VP4 G2A mutation to prevent myristoylation (18, 54, 55). 208 
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These expression constructs lack FMDV Lpro normally found as a self-cleaving protease 209 
upstream of VP4, and contain an additional methionine residue to initiate translation at 210 
the start of VP4. The G2A notation here takes into account the additional methionine at 211 
the N-terminus of VP4, which is removed by host enzymes to reveal the myrisoylation 212 
signal (56).   As expected, this mutation successfully prevented myristoylation in RRLs 213 
(fig. 4D), and completely prevented pentamer formation (fig. 4E) but did not prevent 214 
processing of the P1Δ2A (fig. 4F).  215 
 216 
Hsp90 inhibition by 17-DMAG reduces processing and pentamer formation in a 217 
dose dependent manner in a cell-free assay. The cell-free processing and assembly 218 
assay described above was adopted to examine the involvement of hsp90 in pentamer 219 
assembly. In these experiments, plasmids expressing capsid precursor with a full-length 220 
2A (fig 1D. pBG200-P1-2A), instead of a truncated 2A (P1-Δ2A), were used, in the 221 
event that the full length sequence was required for an appropriate interaction with heat 222 
shock proteins to occur. The pBG200-P1-2A plasmid was used to program RRLs that 223 
were pre-treated with a 10-fold dilution series of 17-DMAG prior to initiation of 224 
transcription and translation. In addition to using the drug at non-toxic concentrations, 225 
higher concentrations of 17-DMAG (beyond the cell culture toxicity limit) could also be 226 
tested in this system. P1-2A was then processed by the addition of recombinant 3Cpro 227 
and pentamer assembly analysed by SDG as described above. In the absence of drug, 228 
gradient peaks were observed with the expected sedimentation for capsid precursors, 229 
protomers (both 5S) and assembled pentamers (14S). In the presence of 17-DMAG, 230 
pentamer formation was reduced in a dose-dependent manner and at a 17-DMAG 231 
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concentration of 1 mM, pentamer assembly was completely prevented (fig. 5A). At 10, 232 
100 and 1000 µm drug concentrations unprocessed P1-2A was also detected in 233 
increasing amounts by autoradiography (fig. 5B) indicating a dose dependent inhibition 234 
of processing at these conditions.   235 
 236 
To determine whether inhibition of pentamer assembly was a direct result of precursor 237 
being unable to multimerise, or was caused indirectly by an inhibition of 3Cpro 238 
processing, reactions (capsid precursor and 3Cpro) were pre-treated with 10µM 17-239 
DMAG or mock treated and processing of the polyprotein assessed at several 240 
timepoints by separating radiolabelled products by SDS-PAGE and detecting by 241 
autoradiography. This showed that P1-2A was processed into intermediate precursor 242 
products and end-point products (VP0, VP3 and VP1) as expected and that in the 243 
presence of 17-DMAG this processing appeared to be delayed (fig. 6A). In these 244 
experiments lower concentrations of 3Cpro (0.25µM) were used to  allow the 245 
visualisation of processing intermediates, ensuring reactions had not reached 246 
completion (where potential differences in reaction rates could be masked by only 247 
analysing end point products). Autoradiographs were analysed by densitometry to 248 
quantitate the rate of processing. This confirmed that the rate of cleavage of P1-2A into 249 
all end point products (VP0, VP3 and VP1) was retarded in the drug treated condition 250 
(Fig 6B) demonstrating that 17-DMAG was affecting the rate of protomer formation.  251 
  252 
 o
n
 January 10, 2018 by Im
perial College London Library
http://jvi.asm.org/
D
ow
nloaded from
 
13 
 
An alternative hsp90 inhibitor, luminespib also inhibits P1-2A processing  253 
In order to confirm that the reduction in FMDV growth was due to the inhibition of hsp90 254 
and not an off-target effect of the 17DMAG, a different class of hsp90 inhibitor was also 255 
tested. Luminespib resembles the macrocyclic lactone antibiotic radicicol which similarly 256 
with 17DMAG (a geldanamycin derivative) binds to the N-terminal domain nucleotide 257 
binding pocket of hsp90, inhibiting its ATPase activity, and subsequent ability to change 258 
conformation to fold client proteins (49). To confirm that this structurally different 259 
inhibitor had a similar effect to 17DMAG, cells were treated with a 2.5-fold dilution series 260 
of luminespib before infection with FMDV at MOI 0.01 and at 72hpi cell viability was 261 
assessed (as described previously). At concentrations above 0.16µM the cells were fully 262 
protected from cpe induced loss in viability (fig 7a). To confirm luminespib inhibited P1-263 
2A processing, RRL expressing P1-2A were pre-treated with a 10-fold dilution series of 264 
luminespib or mock treated with DMSO and the processing phenotype was analysed by 265 
autoradiography (fig. 7b). A dose dependent inhibition of P1-2A processing was indeed 266 
evident, at higher concentrations of this drug. 267 
268 
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Discussion 269 
Capsid assembly of enteroviruses has been shown to require hsp90 (37, 38, 40-42), but 270 
this is not true of all members of the picornavirus family (57). Here we have investigated 271 
the requirements for FMDV (genus Aphthovirus) assembly and provide evidence of a 272 
role for the cellular chaperone hsp90 in the processing of the capsid precursor, which is 273 
a vital step required for precursor multimerisation into a pentameric subunits and capsid 274 
assembly. Pharmacological inhibition of hsp90 resulted in dose-dependent reduced viral 275 
growth in cell culture, without effecting translation or replication of a sub-genomic 276 
reporter replicon. Hsp90 inhibition was shown to reduce P1-2A processing and 277 
pentamer formation in a cell-free system, therefore demonstrating that FMDV assembly 278 
requires the cellular chaperone machinery.  279 
 280 
Picornavirus assembly has previously been demonstrated to proceed through several 281 
closely linked stages. For most picornaviruses, the nascent viral polyprotein is co-282 
translationally myristoylated by host enzymes and the capsid precursor is separated 283 
from the other translation products via proteolysis or a ribosomal “skipping” mechanism. 284 
Capsid precursors are then processed by the viral 3C or 3CD protease facilitating their 285 
multimerisation into a pentameric capsid subunit and encapsidation of the viral RNA to 286 
form virions, or empty capsid in the absence of RNA (6). However, it is now clear that, 287 
this simple description of capsid assembly is incomplete and, recent evidence suggests 288 
the requirement for interactions of the picornavirus capsid precursor with chaperones 289 
such as hsp90. Inhibition of hsp90 has been shown to lead to the increased turnover of 290 
viral proteins from a diverse range of families (35). The capsid proteins of poliovirus, 291 
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and human and murine noroviruses (members of the calicivirus family) (44) have been 292 
shown to require hsp90 for the stability of their capsid proteins, and for poliovirus this 293 
was attributed to an inhibition of capsid precursor processing (37). Viral capsids are 294 
composed of multimeric copies of a single repetitive subunit which must associate 295 
correctly to encapsidate the viral genome, while retaining the functionality required to 296 
enter new cells (58). Due to the multimeric nature of viral capsids, a lack of control 297 
during assembly is likely to result in protein misfolding which can be detrimental to the 298 
virus by generating proteins with a dominant negative phenotype, capable of “poisoning” 299 
capsid assembly (59). To prevent this, it appears that viruses across different families 300 
have developed a requirement for cellular chaperones to maintain the stability of their 301 
capsid proteins during assembly. This suggests a common requirement for correctly 302 
folded proteins in order for correct capsid processing and assembly to proceed. 303 
 304 
In our study, a cell-free assay was used (in rabbit reticulocyte lysates) to specifically 305 
analyse the precursor processing and pentamer assembly stages of FMDV capsid 306 
assembly. N-terminal myristoylation of the precursor has previously been shown to be 307 
required for picornavirus capsid assembly by stabilising pentamer formation (18, 19), 308 
vital for efficient capsid formation (54, 60, 61, 62). Consistent with these observations, in 309 
our system the assembly of capsid precursors into pentamers was prevented by 310 
mutation of the myristoylation signal in P1.  311 
 312 
The cell-free assay demonstrated a dose-dependent inhibition of both capsid precursor 313 
processing and pentamer assembly in the presence of inhibitors of hsp90 which is a 314 
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critical step in the formation of new FMDV virions. This conclusion is supported by 315 
findings that treatment with 17DMAG and luminespib  resulted in a dose-dependent 316 
inhibition of virus growth in cell culture. There was a reduction in virus yield of more than 317 
one log when cultures were treated with 10µM 17DMAG which contrasted with a 50% 318 
reduction in pentamer formation caused by 17-DMAG in the cell-free assay. The reason 319 
for the difference in the magnitude of the effect could be due to differences in the nature 320 
of the assays. For example in cells, delays in capsid protein folding result in its 321 
degradation (37) which might contribute to the reduction in virus yield.  322 
 323 
When the rate of processing was considered in the cell-free assay it was clear that 324 
processing of P1-2A was delayed by the addition of 17-DMAG suggesting that either 325 
hsp90 was not completely inhibited by the drug, or that P1-2A was able to fold into a 326 
conformation required for processing without hsp90, but that this occurred more slowly 327 
or less efficiently in the presence of the drug. Interestingly, in figures 5 and 7, when 328 
hsp90 was inhibited, processing intermediates were not detected. We interpret this to 329 
mean that when functional hsp90 is in short supply, P1-2A may exist as two pools, one 330 
where precursor is folded correctly and cleaved rapidly by the high concentration of 3C 331 
to leave no processing intermediates, and a second pool of precursor molecules not yet 332 
folded correctly and which cannot be processed, hence remaining as intact P1-2A. 333 
     334 
The canonical model for protein folding in the cytosol is that nascent polypeptides are 335 
protected from misfolding by chaperone complexes involving another heat shock 336 
protein, hsp70. Some proteins can then be cycled into an additional folding pathway that 337 
 o
n
 January 10, 2018 by Im
perial College London Library
http://jvi.asm.org/
D
ow
nloaded from
 
17 
 
involves hsp90 (63-67). In the current study, perhaps hsp70 chaperone complexes are 338 
sufficient to initiate P1-2A folding into the correct conformation but this process is more 339 
efficient if hsp90 is involved. Interestingly, a previous study identified an interaction 340 
between hsp70 and the P1 of enteroviruses (PV and coxsackie virus B1) (42), therefore 341 
treating cell-free assays with inhibitors of the hsp70 system in addition to 17DMAG may 342 
have an additive effect in preventing FMDV P1-2A folding and subsequent processing.  343 
 344 
For viral polyproteins that are processed by cleavage at multiple sites, such as in 345 
FMDV, there is evidence for the cleavages to occur in a preferred order (68). In 346 
addition, in PV, mutations which increased the rate of cleavage at the VP0/VP3 junction, 347 
resulted in a virus with a reduced growth rate (69). The preferential ordering of multiple 348 
cleavages may be controlled by the different sites being cleaved with different 349 
efficiencies. Sequential processing may provide a functional benefit to the virus such as 350 
facilitating a subtle conformational alteration required for the next cleavage to occur. In 351 
addition, some processing events may involve distant parts of the polyprotein. For 352 
example, a recent study identified a substitution at the FMDV P1/2A junction which 353 
prevented this cleavage and resulted in the generation of a compensatory mutation 354 
distant in sequence and structure from this site (70). Such long-range requirements for 355 
cleavage could suggest that such distant sites are involved in the interaction between 356 
P1-2A and hsp90.  357 
 358 
From the results presented here, it is likely that hsp90 increases the efficiency of FMDV 359 
capsid precursor folding and subsequent virion assembly. Using hsp90 inhibitors, 360 
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studies with poliovirus have indicated it is not possible to select viruses with a resistant 361 
phenotype (37). A major problem for the control of FMD outbreaks in normally disease-362 
free countries is the delay in onset of immunity following emergency vaccination. 363 
Antiviral compounds have the potential to provide vital protection during this delay (71). 364 
Preventing or reducing FMDV assembly as demonstrated here by 17-DMAG and 365 
luminespib in vitro provides a potential antiviral strategy to help control outbreaks until 366 
the onset of immunity following vaccination, and provides a novel method by which to 367 
understand further the FMDV assembly pathway.  368 
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Materials and Methods: 369 
Cells, virus and inhibitors. FMDV strain O1 Manisa was propagated in Baby hamster 370 
kidney (BHK-21) and pig kidney (IB-RS-2) cell lines which were obtained from the 371 
central services unit (CSU) at The Pirbright Institute. BHK-21 cells were grown in 372 
Glasgow’s MEM (GMEM; Life Technologies), with 10% foetal bovine serum (FBS), 2mM 373 
L-Glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin and 5% tryptose 374 
phosphate broth (TPB, CSU). IB-RS-2 cells were grown in the same media as BHK-21 375 
cells but with 10% adult bovine serum (ABS; Life technologies) substituting FBS. During 376 
luminescence counting experiments, cells were maintained in DMEM lacking phenol-red 377 
indicator (Life technologies). 378 
 379 
Hsp90 inhibitors; 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-380 
DMAG, Invivogen CAS# 467214-21-7) and Luminespib (NVP-AUY922, Selleckchem 381 
CAS# 747412-49-3) were reconstituted in deionised water or DMSO respectively, 382 
aliquoted and frozen at -80oC. These stocks of drugs were diluted into cell culture 383 
medium or reticulocyte lysate before use.  384 
 385 
Cytotoxicity assay. Cellular toxicity caused by Hsp90 inhibition was measured using a 386 
luminescent cell viability assay based on quantitation of ATP (Tox-Glo, Promega). Cells 387 
were grown in μclear 96-well plates (Greiner Bio-One) and maintained in phenol red-388 
free DMEM (Life Technologies). A dilution series of drug inhibitor was made in phenol 389 
red-free media and 100 μl replaced the media in each well. For antiviral dose-response 390 
experiments, FMDV was added at MOI 0.01. At the end of the toxicity period required, 391 
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room temperature ATP detection reagent was added to ATP detection substrate, mixed 392 
thoroughly and 100 μl was added to each well. After 10 minutes, luminescence was 393 
detected using a Chameleon V platereader (Hidex). 394 
 395 
Virus titration. Virus infectivity was titrated by end-point dilution. Serially diluted 396 
samples were used to infect BHK-21 cells in 96-well plates and the 50% Tissue culture 397 
Infective Dose (TCID50) calculated using the Reed-Muench method (Reed and Muench, 398 
1938). 399 
 400 
Sub-genomic replicon assay to quantitate replication of FMDV RNA. Replicon RNA 401 
was transcribed in vitro from cDNA plasmids in which the majority of the structural 402 
proteins had been replaced with a reporter gene as described by Tulloch and 403 
colleagues (50). In this case the reporter gene encoded Renilla-luciferase. To perform 404 
the assays, IB-RS-2 cells were grown in μclear 96-well plates (Greiner) using phenol 405 
red-free DMEM. Media was removed from the wells and replaced with triplicate 406 
conditions of fresh media or drug treatment and the cells were incubated for one hour at 407 
37oC. The cells were transfected with 90ng of FMDV replicon RNA and 1 μl of 408 
Lipofectamine 2000 (Thermo) per well according to the manufacturer’s instructions. 409 
EnduRen Live Cell Substrate (Promega) was prepared in fresh media (with drug 410 
treatments as required) and added to cells on top of the transfection mixtures. 411 
Luminescence was read periodically on a Chameleon V platereader (Hidex). 412 
 413 
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Bacterial expression and purification of 3Cpro. A pET28b plasmid encoding the 414 
Δ3B1-3B2-3B3-3C-His6
 
sequence from FMDV A1061 with two mutations to enhance 415 
enzyme solubility (C95K/C142A) was obtained from Stephen Curry at Imperial College 416 
London (51). E.coli BL21 (DE3) pLysS were transformed with this plasmid and grown to 417 
an optical density at 600 nm of 0.4-0.7 absorbance units. Expression was induced by 418 
the addition of 1mM Isopropyl-β-D-thio-galctosidase (IPTG; Sigma) for four hours at 419 
37°C. Bacteria were harvested by centrifugation and resuspended in a lysis buffer 420 
containing 50 mM HEPES pH 7.1, 200 mM NaCl, 1 X HALT protease inhibitor cocktail 421 
(Thermo Fisher Scientific), 1% Igepal CA-630 (Sigma), 100 μg/mL lysozyme, 100 μg/mL 422 
DNase (Invitrogen) on ice for one hour. Lysates were subjected to 12, 30 second 423 
sonication cycles at amplitude of 10 microns (Microson XL-2000, Misonix) with 30 424 
seconds on ice between each sonication. Lysates were clarified by centrifugation and 425 
his-tagged 3Cpro
 
purified by nickel-ion affinity chromatography using HisTrap columns 426 
(GE Healthcare). Elution fractions were analysed by SDS-PAGE and fractions with the 427 
highest concentration of purified protein were pooled and dialysed against 50mM 428 
HEPES pH7.1, 0.2M NaCl, 1mM EDTA, 1mM β-mercaptoethanol and 5% glycerol. 429 
Purified dialysed proteins were stored at -80
o
C. 430 
 431 
Cell-free processing and pentamer assembly assay. FMDV capsid expression 432 
constructs were created using standard molecular biology techniques (72). A plasmid 433 
encoding the capsid and 3C protease genome regions of the O1Manisa strain of FMDV 434 
in pBG200 T7 expression vectors (11) were used as a template to generate the 435 
plasmids pBG200-P1-2A, pBG200-P1-Δ2A with the primer sequences described in 436 
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table 1 by PCR. The Δ2A versions of P1 were designed to encode the first 12 bases of 437 
the 2A protein coding region followed by a his6 tag to allow purification in other 438 
experiments. For the chaperone experiments, it was deemed important to express the 439 
complete 2A region and so the pBG200-P1-2A plasmids were generated.  PCR 440 
reactions were performed using KOD polymerase (Roche) and a VP0 G2A substitution 441 
to prevent myristoylation was introduced into the coding sequence of pBG200-P1-Δ2A 442 
to generate pBG200-P1-2A-G2A using Quikchange Lightning mutagenesis (Agilent) and 443 
the primer sequences described in table 1.  444 
 445 
Radiolabelled P1-2A was generated from plasmids using in vitro transcription and 446 
translation reactions in rabbit reticulocyte lysates (TnT quick; Promega) according to the 447 
manufacturer’s instructions. Reactions contained 20 ng/µl plasmid DNA, 8 Bq/µl 35S 448 
methionine (EasyTag; Perkin Elmer) and various concentrations of Hsp90 inhibitor and 449 
were incubated at 30°C for 1.5 hours. Processing and assembly of P1-2A into 450 
pentamers was achieved by the addition of 1 µM 3Cpro to the reaction and incubation at 451 
37°C for 1 hour. Following incubation, free radiolabel was removed from reactions by 452 
dialysis at 4°C against PBS, using mini dialysis units (Slide-A-Lyzer, Pierce) that had 453 
been pre-blocked with 1% BSA in PBS. 454 
 455 
SDS-PAGE and fluorography. Products of processing reactions were seperated by 456 
SDS-PAGE. Gels were soaked in 1M sodium salicylate (VWR) for 30 minutes, dried on 457 
a slab gel dryer (DrygelSR) for 1 hour at 80°C, exposed to film at -80°C overnight and 458 
developed using standard photographic reagents. Digital images of gels and films were 459 
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generated using a scanner (Epson). The images that are presented were de-coloured, 460 
and the contrast and brightness settings adjusted minimally using Adobe Photoshop. 461 
Relative band intensity was quantified on scanned film images for each cleavage 462 
product using NIH Image J software (v.1.5)(73).  Signals used to generate data were 463 
determined to be within the linear range of the film by comparison of multiple exposures.  464 
 465 
Sucrose density gradients. Sucrose density gradients (SDGs) were used to separate 466 
capsid precursors and protomers from pentameric capsid components. Gradients were 467 
prepared in 5mL ultracentrifuge tubes (polyclear; Biocomp) using the Gradient Master 468 
system (Biocomp). After the gradient was formed, a volume of 240 μl sucrose solution 469 
was removed from the top of the gradient and the samples were diluted to this volume 470 
in PBS and layered on top of the sucrose. The tubes were subjected to 471 
ultracentrifugation for 6 hours at 367598 x g max, 286794 x g average at 10°C in a 472 
SW55Ti rotor (Beckman).  473 
 474 
Following ultracentrifugation, gradients were fractionated into equal fractions using a 475 
Piston Gradient Fractionator (Biocomp). Radioactive SDG fractions were diluted 1:5 in 476 
Optiphase Supermix (Perkin Elmer) and counted in scintillation vials for three minutes 477 
on an LS6500 Multi-purpose scintillation counter (Beckman). 478 
479 
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Figure Legends 706 
Figure 1: FMDV genome and expression constructs 707 
A. Representation of the FMDV genome showing mature protein products in boxes, 708 
non-coding regions (NCR), viral protein genome-linked (VPg) representated with an 709 
oval. B. Sub-genomic replicon based upon the O1K FMDV sequence encoding renilla 710 
luciferase in place of the majority of the capsid. C. pET28b plasmid expression 711 
constructs encoding 3C protease with C95K/C142A solubility mutations (51). D. Plasmid 712 
expression constructs encoding full length capsid precursor (P1-2A), capsid precursor 713 
with only the cleavage recognition sequence at the start of 2A (P1-Δ2A), P1-Δ2A 714 
encoding a G2A mutation in VP4 to prevent myristoylation (P1-Δ2A G2A). All capsid 715 
precursor constructs were under the control of a T7 promoter in the pBG200 backbone 716 
(11). 717 
Protein processing key: Cleavages performed by 3Cprotease , ribosomal skip , 718 
autocatalytic cleavage by Lprotease , Maturation cleavage . 719 
 720 
Figure 2: 17-DMAG reduces the growth of FMDV in cell culture without affecting 721 
translation or replication of the RNA 722 
A. BHK21 cells were treated with 17-DMAG at the concentrations indicated or mock 723 
treated before infection with FMDV strain A22 Iraq.  Cells were lysed 8 hours post 724 
infection and infectious virus titrated by TCID50 assay. Replicates represent 725 
independent experiments. B.  IB-RS-2 cells were treated with 17-DMAG (0.5µM) or Gu-726 
HCl (3mM) for 30 minutes at 37oC before being transfected with FMDV replicon RNA. 727 
Luciferase production was measured at half hour intervals and expressed as relative 728 
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light units (RLU). Errors represent the standard deviation of triplicate samples. C. 17-729 
DMAG cytotoxicity: Cultures of IB-RS-2 and BHK21 cells were treated with a dilution 730 
series of 17-DMAG for 8 hours at 37°C.  Cell viability was determined by quantitating 731 
cellular ATP using a luminescence assay (Promega ToxGlo) and luminometer (Hidex 732 
Chameleon). Values were converted to % relative light units (RLU) obtained from mock 733 
treated normal healthy cells. Errors represent standard deviations of quadruplicate 734 
samples.  735 
 736 
Figure 3: 17DMAG inhibition of virus growth is dose-dependent. BHK-21 cells were 737 
treated with a 2.5-fold dilution series of 17DMAG (A) or GuHCl (B). The cells were 738 
infected with FMDV at MOI 0.01 () or mock infected () and incubated for 72 hours at 739 
37°C. Cell viability was determined by quantitating cellular ATP using a luminescence 740 
assay (Promega ToxGlo) and luminometer (Hidex Chameleon). Values were converted 741 
to % relative light units (RLU) obtained from healthy cells. Errors represent standard 742 
deviations of quadruplicate samples. 743 
 744 
Figure 4: Validation of the cell-free assay for FMDV capsid precursor processing 745 
and pentamer assembly 746 
A. P1-2A processing assay validation. P1-Δ2A capsid precursor generated from 747 
expression in rabbit reticulocyte lysates was mixed with a range of concentrations of 748 
purified 3Cpro for 1 hour at 37oC and the proteins were resolved on 12% SDS-PAGE 749 
gels, followed by fluorography. B. Marker proteins with known sedimentation were 750 
separated through 5-30% sucrose density gradients with linear regression analysis used 751 
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to extrapolate and interpolate unknowns. C & E. Sucrose density gradient analysis of 752 
pentamer assembly reactions with P1-Δ2A wt (C) and G2A mutant (E) expression 753 
constructs showing mock () and 3Cpro () treatments. D. Cell-free expression of P1-754 
Δ2A wt and G2A expression constructs in the presence of 3H-myristic acid F. Capsid 755 
precursor processing assay using P1-Δ2A-wt and -G2A expression constructs labelled 756 
with S35 - methionine. 757 
  758 
Figure 5: 17DMAG inhibition of hsp90 reduces P1-2A processing and pentamer 759 
assembly in a dose dependent manner 760 
Cell-free expression reactions were pre-treated with the concentrations of 17-DMAG 761 
indicated prior to expression of radiolabelled P1-2A and processing by addition of 762 
purified 3Cpro. A. The majority of the samples were sedimented through 5-30% (w/v) 763 
sucrose density gradients and material in gradient fractions detected by scintillation 764 
counting. B.  Samples were also removed before sedimentation and resolved through 765 
12% SDS-PAGE gels and analysed by fluorography.  766 
 767 
Figure 6: Inhibition of hsp90 reduces the rate of P1-2A processing 768 
A. Cell-free expression reactions were pre-treated with 10 µM 17DMAG or mock-treated 769 
prior to expression of radiolabelled P1-2A and processing by addition of purified 3Cprofor 770 
the times indicated. Samples were resolved through 12% SDS-PAGE gels and 771 
analysed by fluorography. A reduced concentration of 3Cpro was used (0.25µM 772 
compared with 1µM in a standard assay). Relative band intensity was performed on 773 
scanned film images for each cleavage product using NIH Image J analysis software 774 
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(v1.50). B.  Densitometric analysis using Image J software was used to generate 775 
relative band intensity of the image in (A), and this was plotted for the mock and drug 776 
treated conditions over time.  777 
 778 
Figure 7: Luminespib inhibits virus growth and reduces P1-2A processing is a 779 
dose-dependent manner  780 
A. BHK-21 cells were treated with a 2.5-fold dilution series of luminespib and then 781 
infected with FMDV at MOI 0.01 () or mock infected () and incubated for 72 hours at 782 
37°C. Cell viability was determined by quantitating cellular ATP using a luminescence 783 
assay (Promega ToxGlo) and luminometer (Hidex Chameleon). B. Cell-free expression 784 
reactions were pre-treated with luminespib at the concentrations indicated prior to 785 
expression of radiolabelled P1-2A and processing by addition of purified 3Cpro. The 786 
samples were resolved through 12% SDS-PAGE gels and analysed by fluorography. 787 
  788 
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Table 1. Primer sequences for cloning 789 
 790 
 791 
Primer name Nucleotide sequence 5’-3’ 
pBG200-P1-
2A_fwd 
TATAGGATCCGTTTAAACTTTCCACAACTGACACG 
pBG200-P1-
2A_rev 
ATATGGATCCTCAGCGGCCGCTGGGGG 
pBG200-P1-
Δ2A_fwd 
TATAGGATCCGTTTAAACTTTCCACAACTG 
pBG200-P1-
Δ2A_rev 
ATATGGATCCTCAGTGGTGGTGGTGGTGGTGTGCAGCAAAATTTA
GAA-GCTGTTTCACCGGTG 
P1-
Δ2A_G2A_fw
d 
GAAAGGTTACCATGGCAGCCGGGCAATCCAG 
P1-
Δ2A_G2A_re
v 
CTGGATTGCCCGGCTGCCATGGTAACCTTTC 
 792 
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